{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T13:52:42Z","timestamp":1775656362581,"version":"3.50.1"},"reference-count":47,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2021,9,29]]},"DOI":"10.1536\/ihj.21-164","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T22:09:35Z","timestamp":1631830175000},"page":"1096-1105","source":"Crossref","is-referenced-by-count":4,"title":["Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging"],"prefix":"10.1536","volume":"62","author":[{"given":"Bryan D.","family":"Young","sequence":"first","affiliation":[{"name":"Yale University School of Medicine"},{"name":"VA Connecticut Healthcare System"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Moreland","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and Anatomy, University of South Carolina School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsie E.","family":"Oatmen","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and Anatomy, University of South Carolina School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Freeburg","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and Anatomy, University of South Carolina School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zartashia","family":"Shahab","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Herzog","sequence":"additional","affiliation":[{"name":"Section of Pulmonary, Sleep, and Critical Care Medicine, Yale School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Miller","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis G.","family":"Spinale","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and Anatomy, University of South Carolina School of Medicine"},{"name":"Columbia VA Health Care System"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol 2016; 68: 411-21.","DOI":"10.1016\/j.jacc.2016.03.605"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305: 391-9.","DOI":"10.1001\/jama.2011.10"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lynch JP, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med 2014; 35: 372-90.","DOI":"10.1055\/s-0034-1376889"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yazaki Y, Isobe M, Hiroe M, <i>et al<\/i>. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88: 1006-10.","DOI":"10.1016\/S0002-9149(01)01978-6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Slart RHJA, Glaudemans AWJM, Lancellotti P, <i>et al<\/i>. A joint procedural position statement on imaging in cardiac sarcoidosis: from the cardiovascular and Inflammation &amp; Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol 2018; 25: 298-319.","DOI":"10.1007\/s12350-017-1043-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chareonthaitawee P, Beanlands RS, Chen W, <i>et al<\/i>. Joint SNMMI-ASNC expert consensus document on the role of 18 F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Med 2017; 58: 1341-53.","DOI":"10.2967\/jnumed.117.196287"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lee PI, Cheng G, Alavi A. The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis. J Nucl Cardiol 2017; 24: 19-28.","DOI":"10.1007\/s12350-016-0682-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Alvi RM, Young BD, Shahab Z, <i>et al<\/i>. Repeatability and optimization of FDG positron emission tomography for evaluation of cardiac sarcoidosis. JACC Cardiovasc Imaging 2019; 12: 1284-7.","DOI":"10.1016\/j.jcmg.2019.01.011"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Elkington PTG, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006; 61: 259-66.","DOI":"10.1136\/thx.2005.051979"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gonz\u00e1lez AA, Segura AM, Horiba K, <i>et al<\/i>. Matrix metalloproteinases and their tissue inhibitors in the lesions of cardiac and pulmonary sarcoidosis: an immunohistochemical study. Hum Pathol 2002; 33: 1158-64.","DOI":"10.1053\/hupa.2002.129423"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Facco M, Cabrelle A, Calabrese F, <i>et al<\/i>. TL1A\/DR3 axis involvement in the inflammatory cytokine network during pulmonary sarcoidosis. Clin Mol Allergy 2015; 13: 16.","DOI":"10.1186\/s12948-015-0022-z"},{"key":"12","first-page":"1305","volume":"11","year":"2014","unstructured":"12. Birnie DH, Sauer WH, Bogun F, <i>et al<\/i>. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11: 1305-23.","journal-title":"Heart Rhythm","ISSN":"https:\/\/id.crossref.org\/issn\/1547-5271","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.hrthm.2018.11.026","volume":"16","year":"2019","unstructured":"13. Spinale FG, Meyer TE, Stolen CM, <i>et al<\/i>. Development of a biomarker panel to predict cardiac resynchronization therapy response: results from the SMART-AV trial. Heart Rhythm 2019; 16: 743-53.","journal-title":"Heart Rhythm","ISSN":"https:\/\/id.crossref.org\/issn\/1547-5271","issn-type":"print"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ahmadian A, Brogan A, Berman J, <i>et al<\/i>. Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol 2014; 21: 925-39.","DOI":"10.1007\/s12350-014-9901-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET\/CT imaging for cardiac sarcoidosis. J Nucl Cardiol 2017; 24: 413-24.","DOI":"10.1007\/s12350-016-0490-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lortie M, Beanlands RSB, Yoshinaga K, Klein R, DaSilva JN, DeKemp RA. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 2007; 34: 1765-74.","DOI":"10.1007\/s00259-007-0478-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Blankstein R, Osborne M, Naya M, <i>et al<\/i>. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63: 329-36.","DOI":"10.1016\/j.jacc.2013.09.022"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Osborne MT, Hulten EA, Singh A, <i>et al<\/i>. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014; 21: 166-74.","DOI":"10.1007\/s12350-013-9828-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Simonen P, Lehtonen J, Kandolin R, <i>et al<\/i>. F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am J Cardiol 2015; 116: 1581-5.","DOI":"10.1016\/j.amjcard.2015.08.025"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kiko T, Yoshihisa A, Kanno Y, <i>et al<\/i>. A multiple biomarker approach in patients with cardiac sarcoidosis. Int Heart J 2018; 59: 996-1001.","DOI":"10.1536\/ihj.17-695"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kandolin R, Lehtonen J, Airaksinen J, <i>et al<\/i>. Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis. Am J Cardiol 2015; 116: 960-4.","DOI":"10.1016\/j.amjcard.2015.06.021"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Baba Y, Kubo T, Kitaoka H, <i>et al<\/i>. Usefulness of high-sensitive cardiac troponin T for evaluating the activity of cardiac sarcoidosis. Int Heart J 2012; 53: 287-92.","DOI":"10.1536\/ihj.53.287"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Date T, Shinozaki T, Yamakawa M, <i>et al<\/i>. Elevated plasma brain natriuretic peptide level in cardiac sarcoidosis patients with preserved ejection fraction. Cardiology 2007; 107: 277-80.","DOI":"10.1159\/000095518"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Fujiwara W, Kato Y, Hayashi M, <i>et al<\/i>. Serum microRNA-126 and -223 as new-generation biomarkers for sarcoidosis in patients with heart failure. J Cardiol 2018; 72: 452-7.","DOI":"10.1016\/j.jjcc.2018.06.004"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ishiguchi H, Kobayashi S, Myoren T, <i>et al<\/i>. Urinary 8-Hydroxy-2&apos;- deoxyguanosine as a myocardial oxidative stress marker is associated with ventricular tachycardia in patients with active cardiac sarcoidosis. Circ Cardiovasc Imaging 2017; 10.","DOI":"10.1161\/CIRCIMAGING.117.006764"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Myoren T, Kobayashi S, Oda S, <i>et al<\/i>. An oxidative stress biomarker, urinary 8-hydroxy-2&apos;-deoxyguanosine, predicts cardiovascular-related death after steroid therapy for patients with active cardiac sarcoidosis. Int J Cardiol 2016; 212: 206-13.","DOI":"10.1016\/j.ijcard.2016.03.003"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Bost TW, Riches DW, Schumacher B, <i>et al<\/i>. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and interleukin-6 but not interleukin-1 beta. Am J Respir Cell Mol Biol 1994; 10: 506-13.","DOI":"10.1165\/ajrcmb.10.5.8179912"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Amber KT, Bloom R, Mrowietz U, Hertl M. TNF-\u03b1: a treatment target or cause of sarcoidosis? J Eur Acad Dermatol Venereol 2015; 29: 2104-11.","DOI":"10.1111\/jdv.13246"},{"key":"29","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1365-2249.1996.13702.x","volume":"104","year":"1996","unstructured":"29. Nakayama T, Hashimoto S, Amemiya E, Horie T. Elevation of plasma-soluble tumour necrosis factor receptors (TNF-R) in sarcoidosis. Clin Exp Immunol 1996; 104: 318-24.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ziegenhagen MW, Fitschen J, Martinet N, Schlaak M, M\u00fcller-Quernheim J. Serum level of soluble tumour necrosis factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis. J Intern Med 2000; 248: 33-41.","DOI":"10.1046\/j.1365-2796.2000.00685.x"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 2015; 15: 283-94.","DOI":"10.1038\/nri3823"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Jaipersad AS, Lip GYH, Silverman S, Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol 2014; 63: 1-11.","DOI":"10.1016\/j.jacc.2013.09.019"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005; 105: 1405-7.","DOI":"10.1182\/blood-2004-08-3178"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kim HP, Imbert J, Leonard WJ. Both integrated and differential regulation of components of the IL-2\/IL-2 receptor system. Cytokine Growth Factor Rev 2006; 17: 349-66.","DOI":"10.1016\/j.cytogfr.2006.07.003"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Thi Hong Nguyen C, Kambe N, Kishimoto I, Ueda-Hayakawa I, Okamoto H. Serum soluble interleukin-2 receptor level is more sensitive than angiotensin- converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement. J Dermatol 2017; 44: 789-97.","DOI":"10.1111\/1346-8138.13792"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Grutters JC, Fellrath JM, Mulder L, Janssen R, Van Den Bosch JMM, Van Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 2003; 124: 186-95.","DOI":"10.1378\/chest.124.1.186"},{"key":"37","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1161\/01.CIR.98.17.1699","volume":"98","year":"1998","unstructured":"37. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation 1998; 98: 1699-702.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Spinale FG, Janicki JS, Zile MR. Membrane-associated matrix proteolysis and heart failure. Circ Res 2013; 112: 195-208.","DOI":"10.1161\/CIRCRESAHA.112.266882"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Razavian M, Tavakoli S, Zhang J, <i>et al<\/i>. Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. J Nucl Med 2011; 52: 1795-802.","DOI":"10.2967\/jnumed.111.092379"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Sahul ZH, Mukherjee R, Song J, <i>et al<\/i>. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging 2011; 4: 381-91.","DOI":"10.1161\/CIRCIMAGING.110.961854"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Spinale FG, Mukherjee R, Zavadzkas JA, <i>et al<\/i>. Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem 2010; 285: 30316-27.","DOI":"10.1074\/jbc.M110.158196"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42. Su H, Spinale FG, Dobrucki LW, <i>et al<\/i>. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005; 112: 3157-67.","DOI":"10.1161\/CIRCULATIONAHA.105.583021"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Piotrowski WJ, G\u00f3rski P, Pietras T, Fendler W, Szemraj J. The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis. Med Sci Monit 2011; 17: CR598-607.","DOI":"10.12659\/MSM.881987"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Crouser ED, Culver DA, Knox KS, <i>et al<\/i>. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 2009; 179: 929-38.","DOI":"10.1164\/rccm.200803-490OC"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Matsuyama W, Mitsuyama H, Watanabe M, <i>et al<\/i>. Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis. Am J Respir Cell Mol Biol 2005; 33: 565-73.","DOI":"10.1165\/rcmb.2005-0236OC"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Brilha S, Sathyamoorthy T, Stuttaford LH, <i>et al<\/i>. Early secretory antigenic target-6 drives matrix metalloproteinase-10 gene expression and secretion in tuberculosis. Am J Respir Cell Mol Biol 2017; 56: 223-32.","DOI":"10.1165\/rcmb.2016-0162OC"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Tan JL, Fong HK, Birati EY, Han Y. Cardiac sarcoidosis. Am J Cardiol 2019; 123: 513-22.","DOI":"10.1016\/j.amjcard.2018.10.021"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/62\/5\/62_21-164\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T05:19:14Z","timestamp":1715145554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/62\/5\/62_21-164\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.21-164","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"article-number":"21-164"}}